104 related articles for article (PubMed ID: 1550771)
1. Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of a poor prognosis in adult Hodgkin's disease.
Grimfors G; Andersson B; Tullgren O; Giscombe R; Holm G; Johansson B; Björkholm M
Br J Haematol; 1992 Feb; 80(2):166-71. PubMed ID: 1550771
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of serum CD8 antigen levels in adult patients with Hodgkin's disease.
Gause A; Verpoort K; Roschansky V; Tschiersch A; Hasenclever D; Schmits R; Diehl V; Brosteanu O; Pfreundschuh M
Ann Oncol; 1991 Sep; 2(8):579-83. PubMed ID: 1724380
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
[TBL] [Abstract][Full Text] [Related]
4. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors.
Orditura M; De Vita F; Roscigno A; Auriemma A; Infusino S; Catalano G
Int J Mol Med; 1998 Jul; 2(1):75-9. PubMed ID: 9854147
[TBL] [Abstract][Full Text] [Related]
5. Decrease in soluble CD8 antigen levels in splenectomized patients as an index for reduced suppressor/cytotoxic cell activity.
Weiss C; Wulf G; Ho AD; Hunstein W
Immunol Lett; 1991 Sep; 30(1):113-8. PubMed ID: 1683649
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
[TBL] [Abstract][Full Text] [Related]
7. Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome.
Pui CH; Ip SH; Thompson E; Dodge RK; Brown M; Wilimas J; Carrabis S; Kung P; Berard CW; Crist WM
Blood; 1989 Jan; 73(1):209-13. PubMed ID: 2521294
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long-term follow-up.
Tullgren O; Grimfors G; Holm G; Johansson B; Svedmyr E; Wedelin C; Mellstedt H; Merk K; Björkholm M
Cancer; 1991 Aug; 68(4):768-75. PubMed ID: 1855177
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease.
Nishanian P; Hofmann B; Wang Y; Jackson AL; Detels R; Fahey JL
AIDS; 1991 Jul; 5(7):805-12. PubMed ID: 1909873
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD4 and CD8 in the peripheral blood of patients with multiple sclerosis and HTLV-1-associated myelopathy.
Tsukada N; Matsuda M; Miyagi K; Yanagisawa N
J Neuroimmunol; 1991 Dec; 35(1-3):285-93. PubMed ID: 1955570
[TBL] [Abstract][Full Text] [Related]
11. Increased levels of soluble CD8 and CD4 in patients with infectious mononucleosis.
Yoneyama A; Nakahara K; Higashihara M; Kurokawa K
Br J Haematol; 1995 Jan; 89(1):47-54. PubMed ID: 7833276
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of soluble CD8 molecule in patients with lymphatic filariasis.
Lal RB; Ramzy RM; Gad AA
Immunol Lett; 1990 Oct; 26(1):85-8. PubMed ID: 2148926
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function.
Axdorph U; Porwit-MacDonald A; Sjöberg J; Grimfors G; Ekman M; Wang W; Biberfeld P; Björkholm M
Br J Cancer; 1999 Dec; 81(7):1182-7. PubMed ID: 10584880
[TBL] [Abstract][Full Text] [Related]
14. A distinctive form of soluble CD8 is secreted by stimulated CD8+ cells in HIV-1-infected and high-risk individuals.
Schlesinger M; Chu FN; Badamchian M; Jiang JD; Roboz JP; Goldstein AL; Bekesi JG
Clin Immunol Immunopathol; 1994 Nov; 73(2):252-60. PubMed ID: 7923932
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD8 levels in the CSF and serum of patients with multiple sclerosis.
Maimone D; Reder AT
Neurology; 1991 Jun; 41(6):851-4. PubMed ID: 1904563
[TBL] [Abstract][Full Text] [Related]
16. Five-year survival in Hodgkin's disease. The prospective value of immune status at diagnosis.
van Rijswijk RE; de Meijer A; Sybesma JP; Kater L
Cancer; 1986 Apr; 57(8):1489-96. PubMed ID: 2936444
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte function in untreated Hodgkin's disease: an important predictor of prognosis.
Wedelin C; Björkholm M; Holm G; Ogenstad S; Johansson B; Mellstedt H
Br J Cancer; 1982 Jan; 45(1):70-9. PubMed ID: 6977367
[TBL] [Abstract][Full Text] [Related]
18. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease.
Axdorph U; Sjöberg J; Grimfors G; Landgren O; Porwit-MacDonald A; Björkholm M
Ann Oncol; 2000 Nov; 11(11):1405-11. PubMed ID: 11142480
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of CD8 antigen in childhood lymphoid malignancies: a possible indicator of increased suppressor cell activity in poor-risk patients.
Pui CH; Ip SH; Dodge RK; Carrabis S; Brown M; Crist WM; Berard CW; Kung P; Dahl GV; Murphy SB
Blood; 1988 Sep; 72(3):1015-21. PubMed ID: 2970871
[TBL] [Abstract][Full Text] [Related]
20. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease.
Oudejans JJ; Jiwa NM; Kummer JA; Ossenkoppele GJ; van Heerde P; Baars JW; Kluin PM; Kluin-Nelemans JC; van Diest PJ; Middeldorp JM; Meijer CJ
Blood; 1997 Feb; 89(4):1376-82. PubMed ID: 9028961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
